We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Bispecific Antibody Neutralizes Both Omicron and Delta Variants of SARS-CoV-2 in Studies with Live Virus

By HospiMedica International staff writers
Posted on 07 Jan 2022
Print article
Illustration
Illustration

An innovative bispecific antibody has been found to bind to and neutralize the Omicron and Delta variants of SARS-CoV-2 in live virus studies.

RBT-0813, a VHH bispecific antibody discovered by Revelar Biotherapeutics (Bethesda, MD, USA) and Twist Bioscience (South San Francisco, CA, USA), binds to the RBD (receptor binding domain) and appears to bind also outside of the RBM (receptor binding motif) of the SARS-CoV-2 spike protein, making it potentially less prone to escape mutations which are often concentrated in the RBM.

According to the new in vitro binding and neutralization data, binding and kinetic data were generated through Surface Plasmon Resonance (SPR) and independently confirmed by flow cytometry. The live virus plaque-reduction data were generated using live SARS-CoV-2 virus from ancestral, as well as the Omicron (B.1.1.529/BA.1) and Delta (B.1.617.2) variants of concern (VOC) isolated from patient nasopharyngeal specimens.

“With this data, we have now confirmed that RBT-0813 binds to and neutralizes both the Delta and Omicron variants of concern in pre-clinical laboratory testing,” said Glenn Marina, CEO of Revelar Biotherapeutics. “We are working diligently to complete preclinical and CMC development to support an IND and the initiation of clinical studies in humans. In parallel, we are in discussions with the U.S. Food and Drug Administration and expect to submit our IND in 1H2022.”

“We are encouraged by these positive results, building on data from peer-reviewed publications in Science and a recent publication in mAbs, that demonstrated Twist Biopharma’s ability to discover the individual antibodies used to build the bispecific RBT-0813,” said Emily M. Leproust, Ph.D., Chief Executive Officer and Co-Founder of Twist said. “These new results indicate that RBT-0813 could potentially offer treatment for patients infected with the most prevalent strains of COVID-19.”

Related Links:
Revelar Biotherapeutics 
Twist Bioscience 

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Ultra Low Floor Level Bed
Solite Pro

Print article

Channels

Critical Care

view channel
Image: AI can be as good as a physician at prioritizing which patients need to be seen first (Photo courtesy of 123RF)

AI Can Prioritize Emergecny Department Patients Requiring Urgent Treatment

Emergency departments across the world are facing severe overcrowding and excessive demands, but a new study indicates that artificial intelligence (AI) might soon assist in prioritizing patients who require... Read more

Surgical Techniques

view channel
Image: The robot`s segments can flatten and extend into cylinders (Photo courtesy of Princeton)

Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends

Soft robots often face challenges in being guided effectively because adding steering mechanisms typically reduces their flexibility by increasing rigidity. Now, a team of engineers has combined ancient... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more